Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

6.820 +0.120 (+1.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Verrica Posts Profit in Fiscal Q2
Via The Motley Fool
Topics Intellectual Property
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
What to Expect from Verrica Pharmaceuticals's Earnings
 
Via Benzinga
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Outlook For Verrica Pharmaceuticals
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
 
Via Benzinga
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Provides Business and Operational Update
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.